镥-177-PSMA I&T联合卡培他滨治疗转移性去势抵抗性前列腺癌的Ia期研究
这项3+3剂量递增Ia期研究评估了卡培他滨联合镥-177-PSMA I&T在经重度治疗的mCRPC患者中的安全性和最大耐受剂量。12例患者接受治疗,未观察到剂量限制性毒性,MTD确定为1000 mg/m2。PSA-50缓解率为50%,PSA-PFS为4.7个月(95%CI 2.3-21.6),联合方案安全可耐受。
要点
- 卡培他滨1000 mg/m2联合Lu-PSMA未出现剂量限制性毒性,MTD为1000 mg/m2。
- 总体PSA-50缓解率为50%,PSA-PFS为4.7个月(95%CI 2.3-21.6)。
- 常见治疗相关不良事件为恶心、乏力和腹泻。
核心结论
- 卡培他滨1000 mg/m2联合Lu-PSMA在重度治疗的mCRPC患者中安全可耐受。
- 剂量扩展队列正在进行以进一步评估疗效。
研究设计与样本
- 3+3剂量递增Ia期研究,纳入既往接受≥1种紫杉类和≥1种雄激素受体通路抑制剂且PSMA-PET适合Lu-PSMA的mCRPC男性患者。
- 卡培他滨四个剂量水平(275-1000 mg/m2)第1-14天给药,Lu-PSMA第10天给药,42天为一周期,最多6周期。
- 主要终点为MTD,次要终点包括安全性、PSA-50和客观缓解率、PSA-PFS、临床和影像学PFS及OS。
- 12例患者至少接受一剂Lu-PSMA,中位年龄75岁。
主要发现
- 未发生剂量限制性毒性,MTD确定为1000 mg/m2。
- 常见治疗相关不良事件为恶心、乏力和腹泻。
- 跨剂量水平的PSA-50缓解率为50%,PSA-PFS为4.7个月(95%CI 2.3-21.6)。
- 1例可测量病灶患者达到部分缓解。
- 探索性PSMA PET生物标志物分析为阴性,可能受小样本量限制。
关键数值与推荐
- 卡培他滨剂量水平为275 mg/m2至1000 mg/m2,第1-14天给药。
- Lu-PSMA于42天周期的第10天给药,最多6周期。
- PSA每两周评估,影像学每12周评估。
临床怎么用
- 对于重度治疗的mCRPC患者,卡培他滨1000 mg/m2联合Lu-PSMA可作为安全可耐受的治疗选择。
- 需关注恶心、乏力和腹泻等常见不良事件。
- 疗效仍需剂量扩展队列进一步验证。
局限性
- 样本量小(12例),可能限制生物标志物分析等探索性终点。
- 为Ia期剂量递增研究,疗效数据为初步结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lu-PSMA is an effective therapy for mCRPC. Capecitabine is an established radiosensitiser in several solid tumours and may enhance therapeutic response when combined with radioligand therapy. We evaluated the safety and maximum tolerated dose (MTD) of capecitabine with Lu-PSMA in a heavily pre-treated mCRPC cohort. METHODS: Men with mCRPC previously treated with ≥ 1 taxane and ≥ 1 androgen receptor pathway inhibitor, and deemed suitable for Lu-PSMA on PSMA-PET, were enrolled in a 3 + 3 dose-escalation study. Capecitabine was administered at four dose levels (275 mg/m2 - 1000 mg/m2) on days 1-14, with Lu-PSMA on day 10 of a 42-day cycle, for up to six cycles. The primary endpoint was the MTD; secondary endpoints included safety, PSA-50 and objective response rates (RR), PSA-progression free survival (PFS), clinical and radiological PFS, and overall survival (OS). PSA was assessed every two weeks; imaging every 12 weeks. RESULTS: 12 patients received at least one dose of Lu-PSMA. Median age was 75. No dose-limiting toxicities occurred, establishing the MTD at 1000 mg/m2. Common treatment-related adverse events were nausea, fatigue, and diarrhoea. Across dose levels, the PSA-50 RR was 50%, and PSA-PFS was 4.7 months (95% CI 2.3-21.6). One patient with measurable disease achieved a partial response. Exploratory PSMA PET biomarker analyses were negative, likely limited by small sample size. CONCLUSION: Capecitabine 1000 mg/m2 in combination with Lu-PSMA is safe and tolerable in heavily pre‑treated mCRPC. A dose‑expansion cohort is ongoing to further evaluate efficacy.
引用
- Leslie C, Al-Ogaili Z, Oh L, et al. Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42315637. doi:10.1007/s00259-026-08006-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。